je.st
news
Tag: support
Support the PPB Honor Guard
2015-05-31 07:26:58| PortlandOnline
The Police Bureaus Honor Guard is one of the most distinguished groups representing the City of Portland and the Portland Police Bureau.
DARPA program integrates non-mechanical optical scanning tech on microchip; new class of low-cost, miniature LIDAR could support autonomous vehicle apps
2015-05-30 18:55:33| Green Car Congress
Tags: support
program
class
tech
Facebook Finally Adds Animated GIF Support
2015-05-30 03:02:58| PC Magazine Software Product Guide
You can finally post an animated GIF in your Facebook status update.
Tags: support
finally
gif
adds
LDO Voltage Regulators support double data rate memory.
2015-05-29 14:31:06| Industrial Newsroom - All News for Today
Featuring built-in power MOSFETs, Models NCP51200, NCP51400, NCP51510, and NCP51199 are suited for SDRAM DIMM memories, servers, routers, smartphones, tablets, STBs, and printers. Devices support DDR1, DDR2, DDR3, LPDDR3, DDR4, and LPDDR4 standards with termination voltages down to 500 mV. Operating from -40 to +125°C, each regulator is capable of actively sourcing and sinking full 2.0 A when used with DDR4 and LPDDR4. ICs also offer soft-start, on-chip thermal shutdown, and remote sensing.
Tags: support
data
rate
double
Amgen and Merck Announce Expansion of Collaboration to Support Studies of Talimogene Laherparepvec in Combination with KEYTRUDA (pembrolizumab) in Patients with Head and Neck Cancer
2015-05-29 14:30:32| Merck.com - Product News
Dateline City: THOUSAND OAKS, Calif. and KENILWORTH, N.J. Companies Also Plan to Initiate Phase 3 Trial in Combination for Advanced Melanoma THOUSAND OAKS, Calif. and KENILWORTH, N.J., - May 29, 2015 Amgen (NASDAQ: AMGN) and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgens investigational oncolytic immunotherapy, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Language: English read more
Tags: with
support
head
studies
Sites : [590] [591] [592] [593] [594] [595] [596] [597] [598] [599] [600] [601] [602] [603] [604] [605] [606] [607] [608] [609] next »